Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Mihael H. Polymeropoulos
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
sleep disorders central nervous system disorders |
| gptkbp:foundedYear |
2003
|
| gptkbp:founder |
Mihael H. Polymeropoulos
|
| gptkbp:headquartersLocation |
gptkb:Washington,_D.C.
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vanda Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableDrugApproval |
Hetlioz (tasimelteon) for Non-24-Hour Sleep-Wake Disorder
Fanapt (iloperidone) for schizophrenia |
| gptkbp:numberOfEmployees |
approximately 200 (as of 2023)
|
| gptkbp:product |
Hetlioz
Fanapt Tradipitant |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockSymbol |
VNDA
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.vandapharma.com/
|
| gptkbp:bfsParent |
gptkb:PhRMA
|
| gptkbp:bfsLayer |
6
|